The clinical trial for OTQ923, a genome-edited autologous hematopoietic stem and progenitor cell therapy targeting BCL11A to increase fetal hemoglobin levels, was terminated early due to business reasons, indicating potential strategic shifts within Novartis Pharmaceuticals. The market for sickle cell disease therapies is expanding, particularly with the rise of gene therapies. However, the competitive landscape includes established therapies and emerging gene-editing technologies, necessitating rigorous diligence to assess Novartis's positioning and future strategies in this space.